To investigate the antigen specificity of regulatory T cells capable of preventing transplant rejection, we have developed two different strategies to achieve tolerance to fully mismatched skin grafts in euthymic mice. A combination of nondepleting Abs targeting CD4, CD8, and CD154 (CD40 ligand) induces dominant transplantation tolerance to fully mismatched skin allografts. Such tolerance is antigen-specific, mediated by regulatory T cells, and can be extended through linked suppression to naïve lymphocytes. The same protocol, when combined with allogeneic bone marrow, enables the development of mixed hematopoietic chimerism and deletional tolerance. Although we cannot exclude that some regulatory T cells may persist in chimeric mice, these cells are insufficient to mediate linked suppression. CD4 ؉ CD25 ؉ T cells, whether taken from naïve mice or from mice tolerized through either treatment protocol, were always able to prevent rejection of skin grafts by naïve CD4 ؉ T cells, and did so with no demonstrable specificity for the tolerizing donor antigens. Such data question whether CD4 ؉ CD25 ؉ regulatory T cells alone can account for the antigen specificity of dominant transplantation tolerance. This finding has led to the claim that these same cells are responsible for dominant transplantation tolerance after therapeutic intervention. If so, we would expect CD4 ϩ CD25 ϩ T cells from animals demonstrating dominant tolerance to show evidence of priming and specificity for the tolerated antigen. By the same token, such cells should not be detectable in animals tolerized through deletional mechanisms, where dominant tolerance has been excluded. We have used an Ab mixture of nondepleting CD4, CD8, and CD154 (CD40-ligand) Abs to produce both forms of tolerance to MHC-mismatched transplants. Tolerance induced to skin grafts as the tolerogen exhibited features of dominant tolerance. Tolerance induced to the combination of skin and donor bone marrow (BM), was associated with mixed hematopoietic chimerism and showed no linked suppression, indicating deletion as the likely mechanism. Skin Grafting. Mice were anesthetized with a mixture of 10 mg͞ml hypnodil and 2 g͞ml sublimaze (Janssen, Tilburg, The Netherlands). A total of 0.12 ml per 20 g of body weight was injected i.p. Skin grafting was performed as described elsewhere (5). In short, skin grafting was conducted by transplanting full thickness tail skin (1 ϫ 1 cm) on the lateral flank. Grafts were observed on alternate days after the removal of the bandage at day 8 and considered rejected when no viable donor skin was present. Statistical analysis of graft survival was made by the log rank method.
To investigate the antigen specificity of regulatory T cells capable of preventing transplant rejection, we have developed two different strategies to achieve tolerance to fully mismatched skin grafts in euthymic mice. A combination of nondepleting Abs targeting CD4, CD8, and CD154 (CD40 ligand) induces dominant transplantation tolerance to fully mismatched skin allografts. Such tolerance is antigen-specific, mediated by regulatory T cells, and can be extended through linked suppression to naïve lymphocytes. The same protocol, when combined with allogeneic bone marrow, enables the development of mixed hematopoietic chimerism and deletional tolerance. Although we cannot exclude that some regulatory T cells may persist in chimeric mice, these cells are insufficient to mediate linked suppression. CD4 ؉ CD25 ؉ T cells, whether taken from naïve mice or from mice tolerized through either treatment protocol, were always able to prevent rejection of skin grafts by naïve CD4 ؉ T cells, and did so with no demonstrable specificity for the tolerizing donor antigens. Such data question whether CD4 ؉ CD25 ؉ regulatory T cells alone can account for the antigen specificity of dominant transplantation tolerance. (4) . This finding has led to the claim that these same cells are responsible for dominant transplantation tolerance after therapeutic intervention. If so, we would expect CD4 ϩ CD25 ϩ T cells from animals demonstrating dominant tolerance to show evidence of priming and specificity for the tolerated antigen. By the same token, such cells should not be detectable in animals tolerized through deletional mechanisms, where dominant tolerance has been excluded. We have used an Ab mixture of nondepleting CD4, CD8, and CD154 (CD40-ligand) Abs to produce both forms of tolerance to MHC-mismatched transplants. Tolerance induced to skin grafts as the tolerogen exhibited features of dominant tolerance. Tolerance induced to the combination of skin and donor bone marrow (BM), was associated with mixed hematopoietic chimerism and showed no linked suppression, indicating deletion as the likely mechanism. Skin Grafting. Mice were anesthetized with a mixture of 10 mg͞ml hypnodil and 2 g͞ml sublimaze (Janssen, Tilburg, The Netherlands). A total of 0.12 ml per 20 g of body weight was injected i.p. Skin grafting was performed as described elsewhere (5) . In short, skin grafting was conducted by transplanting full thickness tail skin (1 ϫ 1 cm) on the lateral flank. Grafts were observed on alternate days after the removal of the bandage at day 8 and considered rejected when no viable donor skin was present. Statistical analysis of graft survival was made by the log rank method.
BM Transplantation (BMT)
. BM donors were depleted of T cells with an i.p. injection of 1 mg of the anti-CD8 mAbs YTS156 and YTS169, and the anti-CD4 mAbs YTS191 and YTA3.1 5 days before BM collection (6) . BM was collected by flushing the femurs and tibias with R10 medium. The cells were counted, resuspended in PBS, and injected i.v. into recipient mice.
Tolerance Induction and mAbs. Tolerance was induced in CBA mice by treatment with 1 mg of YTS177.9 (7), 1 mg of YTS105.18 (7) , and 1 mg of MR1 (5) at days 0, 2, and 4 after B10 skin transplantation. All mAbs were produced in our laboratory by culture in hollow fiber bioreactors, purified from culture supernatants by 50% ammonium sulfate precipitation, dialyzed against PBS, and the purity was checked by native and SDS gel electrophoresis (PhastGel, Amersham Pharmacia).
Cell Sorting and Adoptive Cell Transfer. Cells were collected from spleens of adult CBA mice. A single-cell suspension was obtained by passing the splenocytes through a 70-m cell strainer (BD Biosciences, Oxford, U.K.), and the erythrocytes were depleted by water lysis. Cells were counted, diluted in PBS, and were injected i.v. into the tail vein. CD4 ϩ CD25 ϩ and CD4 ϩ CD25 Ϫ T cells were sorted as described (8) . In brief, spleen cells were depleted of CD8 ϩ , B cells, and antigen-presenting cells by incubating them with the mAbs M5͞114, 187.1, and YTS156, followed by incubation with goat anti-rat IgG Dynabeads (Dynal Biotech, Oslo). The enriched population of CD4 ϩ T cells was stained with the biotinylated anti-CD25 mAb 7D4 (BD Biosciences), and positively selected with streptavidin microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) by using an autoMACS (Miltenyi Biotec). The CD4 ϩ CD25 Ϫ T cells were isolated from the CD25-depleted fraction by using positive selection with anti-CD4 microbeads (Miltenyi Biotec). CD4 ϩ T cells were sorted from spleens of CD8-depleted mice, by using A brief treatment with a combination of nondepleting CD4, CD8, and CD154, but not a combination of any two of the mAbs, is capable of inducing tolerance to fully mismatched skin grafts in CBA mice. Adult euthymic mice were transplanted with B10 skin and treated with a short course of nondepleting CD4 (YTS 177), CD8 (YTS 105), and CD154 (MR1) mAbs. Mice treated with a combination of the three mAbs accepted the tolerated skin grafts indefinitely, as did most of the animals treated with anti-CD4 plus anti-CD8 mAbs. All mice treated with other mAb combinations readily rejected the skin grafts (Fig. 1A) .
One hundred days after transplantation, mice with surviving skin allografts received a further donor (B10) skin graft, as did animals treated with all three mAbs in the absence of the initial donor grafts (Fig. 1B) . No rejection was observed in the group rendered tolerant to B10 skin by treatment with the three mAbs. This outcome cannot be a consequence of persistence of mAbs in the circulation, because the control group injected with the same mAbs, but in the absence of an initial graft, readily rejected the transplanted skin. Mice pretreated with just the CD4 and CD8 mAbs showed extended survival of the initial allografts, but rejected both these and new donor skin transplants, albeit slowly, after the secondary graft challenge. Mice tolerized with the three mAbs remained fully competent to reject third-party BALB͞c skin transplants, at a similar rate to nontolerant mAb-treated animals (data not shown).
Tolerance Induced to Transplanted Skin Is Antigen-Specific and Exhibits Linked Suppression. Linked suppression has been a constant feature of dominant transplantation tolerance induced by treatment with nondepleting CD4 or CD154 mAbs (5, 9-11). We found that the combination of the three mAbs induced a very powerful form of linked suppression across fully mismatched skin allografts.
CBA mice were tolerized to B10 skin grafts as described. Fig.  2 shows graft survival for skin transplanted at 100 days. Mice grafted with (B10ϫBALB͞c)F1 skin held their grafts indefinitely, whereas nontolerant mice rejected theirs. When mice were transplanted with both B10 and BALB͞c skin in the same graft bed, BALB͞c grafts were rejected, with two mice from this group subsequently rejecting the B10 grafts (on days 22 and 27, not represented in Fig. 2 ). In a repeat experiment, BALB͞c rejection did not lead to B10 rejection in any animals (n ϭ 5), and in all experiments where BALB͞c and B10 skin grafts were transplanted sequentially, only BALB͞c grafts were rejected. It is possible that in the two mice that had rejected the tolerated B10 grafts, crossreactivity of T cells recognizing antigens presented by donor antigen-presenting cells (direct presentation) overcame the effect of regulatory cells that were maintaining B10 grafts.
Three of six CBA mice tolerized with B10 skin allografts rejected (CBAxBALB͞c)F1 skin transplants at a slower rate, and the remaining mice accepted their grafts indefinitely (Fig.  2) . To confirm that this result was not due to a subtle form of immunosuppression, CBA mice treated with the same mAbs in the absence of a tolerizing graft were shown capable of rejecting (CBAϫBALB͞c)F1 skin grafts at the same rate as BALB͞c skin grafts [n ϭ 7; median survival time (MST) ϭ 14 days vs. 12 days]. Naïve CBA mice readily rejected (CBAϫBALB͞c)F1 or (CBAϫB10)F1 skin grafts. We interpret this result as a form of linked suppression due to regulatory T cells recognizing a set of indirectly processed B10 antigens shared with BALB͞c but foreign to CBA (12) .
One of the potential therapeutic benefits of linked suppression would be the dissemination of tolerance to third-party antigens, which can be obtained by transplanting hosts tolerant to the second party with tissues exhibiting the combination of tolerated and third-party antigens (5, 9-11). We confirmed that this was possible by transplanting BALB͞c skin onto those CBA mice, pretolerized to B10 skin, where (B10ϫBA LB͞c)F1 or (CBAϫBALB͞c)F1 skin had survived 50 days. All of the animals accepted the BALB͞c skin (data not shown). These were treated with three doses of 1 mg of the anti-CD4, anti-CD8, and anti-CD154 nondepleting mAbs over 1 week after B10 skin transplantation at day 0. Only mice treated with the three mAbs (, n ϭ 6, MST Ͼ100 days) and anti-CD4 plus anti-CD8 (OE, n ϭ 26, MST Ͼ100 days) showed indefinite graft survival (P Ͻ 0.05 to any other group). All grafts from mice treated with anti-CD4 plus anti-CD154 (F, n ϭ 6, MST ϭ 21.5 days), anti-CD8 plus anti-CD154 (ࡗ, n ϭ 6, MST ϭ 14 days), and untreated controls (s, n ϭ 10, MST ϭ 10 days) were rejected. (B) After 100 days, mice with surviving skin allografts received fresh B10 skin transplants. In animals treated with the three mAbs, no rejections were observed (ࡗ, n ϭ 6, MST Ͼ100 days). Mice treated with only anti-CD4 and anti-CD8 rejected the skin allografts (, n ϭ 10, MST ϭ 46 days, P ϭ 0.011 vs. ࡗ). The control group treated with the same three mAbs (as ࡗ) in the absence of initial transplant rejected the skin grafts (s, n ϭ 5, MST ϭ 16 days).
results show how tolerance induced to fully mismatched skin grafts can be extended to third-party antigens. To investigate whether tolerance induction would lead to antigen-specific regulation by CD4 ϩ CD25 ϩ T cells, we transplanted CBA mice with either B10 skin or BALB͞c skin under the cover of nondepleting CD4, CD8, and CD154 mAbs as described. Whereas full tolerance can be achieved to B10 skin, such is not the case for BALB͞c grafts with most being eventually rejected (n ϭ 23, MST ϭ 86 days). CD4 Regulation. Previous reports (13, 14) have shown that CD154 mAbs allow the development of stable mixed hematopoietic chimerism, in the absence of myeloablation, when megadoses of donor BM are transplanted. A recent report (15) has shown that the induction of peripheral tolerance can facilitate the induction of hematopoietic chimerism without myeloablation. We used our same tolerizing protocol as above, with the three mAbs targeting CD4, CD8, and CD154, to induce mixed chimerism and tolerance without myeloablative conditioning. We grafted B10 skin onto CBA mice under the cover of the three mAbs as described. One month after this initial treatment, mice were treated with 40 ϫ 10 6 BM cells from T cell-depleted B10 donors with or without an additional mAb course. Pretolerization with a donor skin was not essential, because mice treated initially with mAbs in the absence of a donor graft were able to accept donor skin grafts transplanted at the time of BMT and mAb treatment (Fig.  4A and Fig. 6 , which is published as supporting information on the PNAS web site). It is interesting to note that donor BM given 1 month after tolerance induction abrogated tolerance unless a further course of mAbs was combined with the BMT. Tolerance achieved with donor BM did not manifest as dominant because we could not demonstrate linked suppression [(B10ϫBALB͞ c)F 1 skin grafts were rejected as shown Fig. 4B ]. Flow cytometric analysis of peripheral blood confirmed that mixed chimerism was maintained in the tolerant mice 120 days after BMT (Fig. 4C) . Similar results were obtained by using BALB͞c mice, where the mAb treatment prolongs B10 graft survival without leading to permanent acceptance of skin grafts (Fig. 6) . However, tolerance and long-term hematopoietic chimerism were achieved when donor BMT was associated with the mAb treatment. 2 . Linked suppression across fully mismatched skin transplants. CBA mice were tolerized to B10 skin grafts as described. One hundred days after tolerance induction (day 0 in the graph), mice were transplanted with (CBAϫBALB͞c)F 1 (, n ϭ 6, MST ϭ 80.5 days), (B10ϫBALB͞c)F 1 (ࡗ, n ϭ 6, MST Ͼ150 days) skin grafts, or both BALB͞c and B10 skin grafts onto the same graft bed (only BALB͞c graft survival represented: OE, n ϭ 5, MST ϭ 14 days). Ab-treated mice not transplanted with tolerizing skin were now grafted with B10 skin (s, n ϭ 6, MST ϭ 10.5 days). Naïve mice were transplanted with (B10ϫBALB͞c)F 1 (छ, n ϭ 6, MST ϭ 10 days), (CBAϫBALB͞c)F1 (‚, n ϭ 6, MST ϭ 12 days), or (CBAϫB10)F 1 (ƒ, n ϭ 6, MST ϭ 12.5 days) skin grafts. All tolerized mice grafted with (B10ϫBALB͞c)F 1 skin accepted the grafts (ࡗ, P Ͻ 0.001 to any other group except ; nonsignificant), whereas mice grafted with (CBAϫBALB͞c)F 1 skin showed a delayed rejection with half the mice accepting the grafts indefinitely (, P Ͻ 0.001). T cells from the chimeric mice were coinjected with naïve CD4 ϩ T cells into RAG1 Ϫ/Ϫ mice, rejection of both BALB͞c and B10 skin grafts was prevented. Evidently, CD4 ϩ CD25 ϩ T cells could prevent graft rejection without any obvious specificity for donor antigen in all of the systems tested. Their apparent lack of specificity for donor antigens is clearly inconsistent with the demonstrable antigen specificity of dominant tolerance.
Discussion
To characterize the antigen specificity of CD4 ϩ CD25 ϩ regulatory T cells, we developed two protocols to achieve tolerance to fully mismatched skin grafts. In one protocol, mAbs targeting CD4, CD8, and CD154 achieve dominant tolerance to skin transplants mediated by CD4 ϩ regulatory T cells. Tolerance so induced, manifests as resistance to rejection mediated by transfused naïve lymphocytes, together with ''linked suppression'' directed toward third-party antigens located in a graft, which also exhibits the tolerated set. With the addition of donor BM to the mAb treatment, we achieve recessive tolerance to the donor antigens, maintained through mixed hematopoietic chimerism. We confirmed that this type of tolerance does not rely on regulatory T cells, but rather, on the inactivation of donorspecific clones (16) .
It has been a long-standing assumption that BM engraftment cannot be achieved without the creation of ''space'' through myeloablative conditioning (17) (18) (19) . This dogma has been challenged with reports showing that costimulation blockade is effective in facilitating BM engraftment when ''megadoses'' of donor BM are used (13, 14, 20) , and a recent report showing that BM engraftment can be achieved through prior induction of peripheral tolerance with a smaller dose of BM (15) . We have now shown that simultaneous targeting of costimulatory molecules (with anti-CD154 mAbs) and CD4 and CD8 coreceptors can also facilitate the induction of mixed hematopoietic chimerism in the absence of any myeloablative conditioning, and without the need for megadoses of donor BM. With this protocol, it becomes possible to achieve transplantation tolerance in ''resistant'' strain combinations.
Having developed two strategies to induce tolerance to fully mismatched allografts, one based on regulatory T cells and the other on deletion of alloreactive clones, it became possible to directly assess whether CD4 ϩ CD25 ϩ T cells were wholly responsible for donor antigen-specific dominant transplantation tolerance.
The characteristics of the regulatory T cells mediating dominant transplantation tolerance are still controversial (21) . We have previously shown (8) T cell populations from tolerized mice was compared, both populations exhibited similar regulatory potency when analyzed in relation to their physiological proportions (8) . In this study, we have used a ratio of regulators to effectors of 2:1. When the regulatory potency of CD4 ϩ CD25 ϩ T cells from tolerant mice was tested, suppression was not achieved with a ratio of 1:1 (n ϭ 5; MST ϭ 13 days). For this reason, and in line with recent reports (22) , we calculated that we were at the lowest testable ratio of regulators to effectors. Previous reports (22) (23) (24) have claimed CD4 ϩ CD25 ϩ T cells to be alloantigen-specific. However, none of those experiments were performed in a crisscross manner, and hardly any involved a titration of regulators in relation to effectors. Where specificity was claimed it was only (A) CBA mice were transplanted with B10 skin at day 0, and treated with nondepleting CD4, CD8, and CD154 mAbs, as described. One month after transplantation, at day 28, mice were treated with 4 ϫ 10 7 T cell-depleted B10 BM cells under the cover of the same mAb treatment (G1: s, n ϭ 5), mAbs alone (G2: OE, n ϭ 6), or BM alone (G3: , n ϭ 5). Different mice were treated initially with the mAbs in the absence of a skin graft, followed by a further treatment with mAbs at day 28 (G5: F, n ϭ 6), or BM together with mAbs and a B10 skin graft (G4: ࡗ, n ϭ 5; see treatment table in A). Group G2 (OE, MST ϭ 93 days) was significantly different compared with all other grafted groups (MST Ͼ110 days); P Ͻ 0.001. (B) One hundred days after BM treatment, mice with surviving B10 skin grafts were transplanted with (B10ϫBALB͞c)F 1 skin. MST in days were: G1 ϭ 21, G2 ϭ Ͼ30, G4 ϭ 20, and G5 ϭ 19. Group G2 was significantly different to all other groups; P Ͻ 0.011. (C) All mice were bled 120 days after BMT to quantify the percentage of H2-D bϩ T cells in their peripheral blood by flow cytometry.
Fig. 5.
Regulation by CD4 ϩ CD25 ϩ T cells from chimeric mice shows no specificity for the tolerated antigen. H2-D bϪ CD4 ϩ CD25 ϩ and H2-D bϪ CD4 ϩ CD25 Ϫ T cells were sorted from the spleen of CBA tolerized 100 days before to B10 skin with donor BM and mAb treatment as described. CD4 ϩ T cells were isolated from the spleen of naïve CBA mice. RAG1 Ϫ/Ϫ mice were injected with 10 5 CD4 ϩ T cells alone (F, n ϭ 10; E, n ϭ 5), or together with 2 ϫ 10 5 H2-D bϪ CD4 ϩ CD25 ϩ (s, n ϭ 9; ᮀ n ϭ 4) or H2-D bϪ CD4 ϩ CD25 Ϫ (‚, n ϭ 5) T cells. In two groups of mice, 2 ϫ 10 5 H2-D bϪ CD4 ϩ CD25 Ϫ T cells were injected alone (, n ϭ 10; ƒ, n ϭ 4). The transfused mice were transplanted with B10 (open symbols) or BALB͞c (filled symbols) skin grafts. P values for the comparisons were as follows: vs. ƒ, P Ͻ 0.002; ᮀ vs. E, P Ͻ 0.015; s vs. F, P Ͻ 0.003.
''detected'' at one single ratio of regulators to effectors, and must therefore remain questionable (22) . In contrast to our findings, some of these previous studies (23) showed no regulatory activity for CD4 ϩ CD25 ϩ T cells from naïve mice. CD4 ϩ CD25 ϩ T cells from naïve donors were also shown to attenuate graft-vs.-host disease without obvious host antigen specificity (25) (26) (27) . It is not clear why some observers have data consistent with alloantigen specificity of these cells. An outcome implying apparent specificity could in part be explained by higher ''rejectability'' of the third-party graft used, or deletion by activation induced cell death of nonregulatory alloreactive cells, specific for the tolerated graft, within the CD4 ϩ CD25 ϩ population. Alternatively, it may be that the bulk of CD4 ϩ CD25 ϩ T cells are self-reactive, and that this activity variably obscures the regulatory effect of donor antigen-specific CD4
Here, we unequivocally demonstrate that CD4 ϩ CD25 ϩ T cells whether from naïve or tolerized mice (either protocol) can prevent graft rejection when injected into lymphopenic hosts regardless of the donor antigens.
To exclude that such results were due to crossreactivity between the donor and third-party strains, we examined the regulatory function of CD4 
